ADAR1 Capital Management LLC Boosts Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

ADAR1 Capital Management LLC grew its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 142.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 31,509 shares of the company's stock after acquiring an additional 18,509 shares during the quarter. ADAR1 Capital Management LLC owned about 0.06% of Janux Therapeutics worth $1,687,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. FMR LLC boosted its holdings in Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock valued at $464,189,000 after purchasing an additional 845,266 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Janux Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock valued at $114,379,000 after buying an additional 288,402 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Janux Therapeutics by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 714,956 shares of the company's stock valued at $38,288,000 after buying an additional 52,362 shares during the last quarter. Wellington Management Group LLP raised its stake in Janux Therapeutics by 3,592.9% during the 4th quarter. Wellington Management Group LLP now owns 535,396 shares of the company's stock worth $28,665,000 after acquiring an additional 520,898 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in Janux Therapeutics by 2,519.6% in the fourth quarter. Franklin Resources Inc. now owns 497,287 shares of the company's stock valued at $26,625,000 after acquiring an additional 478,304 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

Remove Ads

Janux Therapeutics Stock Performance

JANX stock traded up $1.93 during midday trading on Friday, hitting $28.80. 2,018,926 shares of the stock were exchanged, compared to its average volume of 858,288. The stock's 50-day moving average price is $31.72 and its 200-day moving average price is $44.16. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -24.62 and a beta of 3.27. Janux Therapeutics, Inc. has a fifty-two week low of $22.52 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JANX. Scotiabank cut their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Lifesci Capital upgraded shares of Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. Finally, Wedbush reissued an "outperform" rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $92.44.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. purchased 341,742 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was bought at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. The trade was a 3.67 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,640,768.85. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders own 29.40% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.